Physician profile
Douglas Keith Epps
NPI 1518957372
$2,647.85
in general payments reported to CMS, 2019-2025
20 companies · $844 in 2025
The $844 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2024: $1,672 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,495 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.39 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $470.25 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic, INC. | $339.82 | 2024-2025 | Minimed 780g, Interstim |
| Xeris Pharmaceuticals, INC. | $297.55 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Lilly USA, LLC | $285.65 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Corcept Therapeutics | $253.90 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.29 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $123.58 | 2024-2025 | |
| Cequr Corporation | $122.61 | 2024-2025 | Cequr Simplicity |
| Boston Scientific Corporation | $117.28 | 2019 | |
| Amgen INC. | $101.49 | 2024-2025 | Tepezza, Prolia, Evenity |
| Radius Health, INC. | $100.35 | 2024 | Tymlos |
| Ascendis Pharma Endocrinology INC | $69.76 | 2025 | Yorvipath |
| Mannkind Corporation | $67.01 | 2024 | |
| Novartis Pharmaceuticals Corporation | $49.52 | 2024-2025 | |
| Verity Pharmaceuticals INC. | $26.67 | 2024 | Tlando |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.63 | 2024 | Veozah |
| Esperion Therapeutics, INC. | $24.32 | 2024 | Nexletol |
| Recordati_rare_diseases_inc. | $16.55 | 2024 | Isturisa, Signifor Lar |
| Abbvie INC. | $15.37 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $15.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Epps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.